Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

Aflibercept (EYLEA®) induces a rapid reduction in central retinal thickness (CRT) for patients suffering from neovascular age-related-macular degeneration.1 This early dramatic reduction in CRT is already observed through week 4. Therefore it might be not necessary to consistently perform each of the three monthly consecutive intravitreal injections of the so-called loading phase.

Inclusion Criteria: * Men and women ≥ 50 years of age * Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affects the fovea as evidenced by FA in the study eye * Signed Informed Consent * Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures. Exclusion Criteria: * Prior treatment with anti-VEGF therapy in the study eye * Active or suspected ocular or periocular infection. * Active severe intraocular inflammation